August 2012
-
Berkley Pharma & Life Science are currently seeking an Equipment Senior Scientist for our client, a leading pharmaceutical company based in Dublin. Ref: 5040180 Role/Opportunity: • Seeking an experienced Manufacturing Equipment specialist with a good… Read more . . .
-
Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well… Read more . . .
-
Contract particle characterization specialist Gateway Analytical has announced that it will host the 2012 Inhalation and Nasal Technology Focus Group (INTFG) Annual Fall Symposium on September 7, 2012 at the Pittsburgh North Marriott in Cranberry,… Read more . . .
-
Submit poster abstracts by August 19, 2012 at the INTFG submission site. Submissions on any inhalation or nasal drug technology topic are welcome. More information. Read more . . .
-
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis.… Read more . . .
-
Entries submitted to several student inhaler and medical device design contests over the past year envision some radical changes in inhaler design. These concepts, created by students who range in age from primary school through… Read more . . .
-
Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones… Read more . . .
-
Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection… Read more . . .
-
According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108… Read more . . .
-
The TOBI Podhaler has been named a bronze winner in the General Hospital Devices and Therapeutics Products division of the Medical Design Excellence Awards presented by UBM Canon and MD+DI. The inhaler, which is marketed… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland